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Abstract
Although animals cannot be used to study complex human behaviour such as language, they do have
similar basic functions. In fact, human disorders that have animal models are better understood than
disorders that do not. ADHD is a heterogeneous disorder. The relatively simple nervous systems
of rodent models have enabled identification of neurobiological changes that underlie certain
aspects of ADHD behaviour. Several animal models of ADHD suggest that the dopaminergic
system is functionally impaired. Some animal models have decreased extracellular dopamine
concentrations and upregulated postsynaptic dopamine D1 receptors (DRD1) while others have
increased extracellular dopamine concentrations. In the latter case, dopamine pathways are
suggested to be hyperactive. However, stimulus-evoked release of dopamine is often decreased in
these models, which is consistent with impaired dopamine transmission. It is possible that the
behavioural characteristics of ADHD result from impaired dopamine modulation of
neurotransmission in cortico-striato-thalamo-cortical circuits. There is considerable evidence to
suggest that the noradrenergic system is poorly controlled by hypofunctional α 2-autoreceptors in
some models, giving rise to inappropriately increased release of norepinephrine. Aspects of ADHD
behaviour may result from an imbalance between increased noradrenergic and decreased
dopaminergic regulation of neural circuits that involve the prefrontal cortex. Animal models of
ADHD also suggest that neural circuits may be altered in the brains of children with ADHD. It is
therefore of particular importance to study animal models of the disorder and not normal animals.
Evidence obtained from animal models suggests that psychostimulants may not be acting on the
dopamine transporter to produce the expected increase in extracellular dopamine concentration
in ADHD. There is evidence to suggest that psychostimulants may decrease motor activity by
increasing serotonin levels. In addition to providing unique insights into the neurobiology of ADHD,
animal models are also being used to test new drugs that can be used to alleviate the symptoms of
ADHD.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the
most commonly diagnosed psychiatric disorder of child-
hood [1,2]. Children with ADHD are characterized by an
inability to sit still, they have difficulty organizing tasks,
they are forgetful, have a tendency to be easily distracted,
fidget, they have difficulty with tasks that require sus-
tained attention and are risk-takers [3,4]. Their behaviour
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falls into two or three core clusters of symptoms, impaired
sustained attention and hyperactivity/impulsiveness that
develops gradually in familiar situations, with impair-
ment manifesting before age 7 [3,5].
The high population prevalence and heritability of ADHD
agrees with ADHD being caused by multiple genes with
small effect size [2,6]. Associations have been found
between polymorphisms in several monoaminergic genes
and ADHD. These include the dopamine D1, D4 and D5
receptor (DRD1, DRD4, DRD5) genes, the α 2-adrenocep-
tor gene, dopamine, norepinephrine and serotonin trans-
porter (DAT1, NET1, SERT1) genes [7-19]. Contradictory
negative findings have also been reported suggesting that
different combinations of genetic factors may combine to
produce individual clusters of behavioural characteristics
of ADHD [20-23]. Different alleles of genes encoding pro-
teins related to dopamine function differentially affect
cognitive function [24]. The effect of a single gene on
behaviour has been described as small causing a slight
bias towards one end of a continuum [4,24].
Numerous studies have found reduced brain volume in
ADHD patients, particularly prefrontal cortex, cerebel-
lum, corpus callosum, and basal ganglia [25-29].
Dopamine alters brain structure and function [24]. The
DAT1 genotype preferentially influenced caudate volume;
individuals homozygous for the 10-repeat allele which is
associated with ADHD had smaller caudate volumes than
individuals carrying the 9-repeat allele [24]. The DRD4
genotype influenced prefrontal gray matter. Individuals
homozygous for the 4-repeat allele had smaller volumes
than individuals carrying other variants of the gene [24].
Imaging studies have demonstrated functional abnormal-
ities in striatum, frontal cortex and cerebellum of patients
with ADHD [30-34].
Imaging studies have revealed robust increases in striatal
DAT of up to 70% in ADHD children and adults
[10,15,35]. Although not every study found increased
DAT [36,37], there is a strong possibility that the DAT1
gene is overexpressed in the striatum of ADHD subjects,
and that this results in reduced synaptic dopamine.
Psychostimulants are highly effective in ameliorating the
three major clusters of behavioural symptoms of ADHD
[38]. Methylphenidate produced improvements in spatial
working memory, attentional set-shifting [39,40], and
inhibition of previously acquired behavioural responses
to non-relevant stimuli [34,41-43]. It increased the previ-
ously reduced striatal activity in patients with ADHD [34]
and reduced cerebral blood flow in frontal and parietal
cortex [39,44].
Animal models of ADHD
Although non-human primate brains are closer to human
brains than rodents, rodent models of ADHD have the
advantage that they are genetically more homogeneous,
they are less expensive to maintain, greater numbers of
experimental animals are available so they are not used
for multiple studies, and much more is known about their
neurobiology than primates. The researcher also has bet-
ter control over variables such as diet, environment, and
learning history. Rodent models have simpler nervous
systems, they cannot be used to study complex cognitive
behaviour like language but their basic behavioural mech-
anisms are similar to humans.
ADHD is a heterogeneous disorder with individual
patients presenting with quite different behavioural
symptoms probably as a result of different combinations
of genetic and environmental factors. Animal models pro-
vide invaluable insight into the neurochemistry underly-
ing specific aspects of ADHD behaviour, when compared
to appropriate controls. Differences between the behav-
iour of an animal model and its control can be correlated
with differences in their neurochemistry and behavioural
pharmacology.
A list of criteria for an optimal animal model of ADHD
was recently suggested [45] (i) the model should mimic
the fundamental behavioural characteristics of ADHD
(face validity), impulsiveness should be absent initially
and develop gradually over time, sustained attention-def-
icit should be demonstrated only when stimuli are widely
spaced in time, hyperactivity should not be observed in a
novel, non-threatening environment, it should develop
over time; (ii) the model should conform to a theoretical
rationale for ADHD (construct validity): the two main
behavioural processes that are proposed to be major con-
tributory factors in the aetiology of ADHD, altered rein-
forcement of novel behaviour and deficient extinction of
previously reinforced behaviour, should be demon-
strated; (iii) the model should predict novel aspects of
ADHD behaviour, genetics, and neurobiology (predictive
validity); and (iv) it should be neurodevelopmental, pref-
erably a genetic model.
We use the concept 'reinforcer' strictly in a behavioural
sense, without making any references to subjective or cog-
nitive states. The alternative concept of 'reward' is more
cognitive and may connote several subjective states like
pleasure as well as incentive and reinforcer [46]. There-
fore, there is not a perfect overlap between reinforcer and
reward. We prefer the more descriptive and less ambigu-
ously defined concept of reinforcer rather than reward [4].
Spontaneously hypertensive rats (SHR) were found to be
the best characterized and also currently the most appro-Behavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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priate model of ADHD [45]. SHR fulfil most of the valida-
tion criteria listed above and compare well with clinical
cases of ADHD [45,47]. Poor performers in the 5-choice
serial reaction time (5-CSRT) task were suggested to be a
useful model for the inattentive subtype of ADHD [45].
Other animal models were suggested to provide useful
information concerning aspects of ADHD behaviour [45].
SHR
SHR exhibit all the behavioural characteristics of ADHD:
impaired sustained attention without obvious sensory
problems, motor impulsiveness, and hyperactivity that is
not present in novel, non-threatening situations but
develops over time when reinforcers are infrequent
[45,47]. Similar to children with ADHD, SHR display
increased behavioural variability, deficient response re-
engagement, and make significantly more errors than con-
trols [45,47,48].
Besides conforming to behavioural criteria for an animal
model of ADHD, SHR fulfils the additional criterion that
it is a genetic model of ADHD bred from progenitor Wis-
tar Kyoto (WKY) rats [49]. WKY serve as a valid control for
SHR since their behavioural characteristics are similar to
those of other rat strains [47]. Three candidate dopamine
genes (DRD2, DRD4, and DAT) were sequenced in SHR
and WKY [Mill et al., unpublished]. No differences were
found in DRD2 or DRD4 genes but a 160 bp insertion was
found in the non-coding region upstream of exon 3 of the
DAT1 gene which is of significance since variable number
tandem repeats in the 3'-untranslated region of the DAT
gene has been associated with ADHD in several family
studies [7,9,10,14,15]. A possible disturbance in the regu-
lation of the DAT1 gene is in agreement with findings that
DAT1 gene expression is transiently reduced in SHR mid-
brain during the first postnatal month and increased in
adult SHR compared to controls [50,51]. Alterations in
DAT1 gene expression can affect dopamine uptake and
reutilization. Decreased expression of DAT1 will reduce
reuptake and increase metabolism of dopamine. Differ-
ences in dopamine metabolism have been reported for
children and adults with ADHD [52,53] which is consist-
ent with developmental changes in DAT1 expression and
consequent changes in dopamine uptake. DOPA decar-
boxylase activity was found to be increased in the mid-
brain of children and decreased in prefrontal cortex of
adults with ADHD compared to controls [52,53].
Reduced DAT1 expression at a young age would reduce
dopamine reuptake, thereby reducing dopamine reutiliza-
tion and necessitating increased synthesis of dopamine by
DOPA decarboxylase. In adults, increased expression of
DAT1 might be expected to increase reuptake of
dopamine, thereby reducing the need for synthesis by
DOPA decarboxylase.
SHR appear to have higher extracellular tonic dopamine
in the nucleus accumbens shell [54]. However, consistent
with increased DAT1 expression in adult SHR striatum,
extracellular dopamine levels are decreased in the caudate
nucleus [55,56] and d-amphetamine-stimulated release
of dopamine via DAT1 is greater in SHR striatum than
WKY [54,57,58]. Evidence suggests that DAT1 is hypo-
functional in SHR, since despite the increased number of
DATs, inhibition of dopamine uptake by low concentra-
tions of methylphenidate or nomifensine increased the
electrically-stimulated release of dopamine to the same
extent in SHR and WKY nucleus accumbens and caudate-
putamen [58,59]. These findings suggest that increased
expression of the DAT1 gene may reflect an attempt to
compensate for increased tonic extracellular dopamine in
the nucleus accumbens shell of SHR or increased DAT1
expression may occur in an attempt to compensate for
decreased function of DAT1 in adult SHR striatum.
Hypertension is a confounding factor in the SHR model of
ADHD. However, SHR do not develop hypertension until
they are adults, from 10 to 12 weeks of age, whereas
hyperactivity is observed at 3 to 4 weeks of age before they
enter puberty [55]. In an attempt to map quantitative trait
loci for complex phenotypes, SHR were crossed with a
Brown Norway congenic strain to generate a set of recom-
binant inbred strains [60]. Analysis of their behaviour
revealed that locomotion mapped to chromosomes 3, 8
and 18 while hypertension exhibited multigenic complex-
ity with both environment and genetic background as
contributing factors. Elevated arterial blood pressure was
higher when measured by direct catheterization com-
pared to radiotelemetry suggesting that SHR hypertension
is a product of stress-dependent trait expression [60]. SHR
behaviour was suggested to result from an interaction
between genetics and the environment [60], much like
ADHD [4,6,23].
In addition to behavioural and genetic similarities to
ADHD, SHR exhibit brain pathology similar to ADHD.
SHR brain volumes, specifically prefrontal cortex, occipi-
tal cortex, and hippocampus, are smaller than controls
[61]. MRI revealed significantly increased ventricular vol-
ume in SHR compared to WKY at 3 months of age [61].
There are fewer neurons in these brain areas compared to
WKY [62-64].
Results obtained with SHR have predicted novel alterna-
tives to existing theories concerning the aetiology of
ADHD. A major second messenger system involving cal-
cium signalling is dysfunctional in SHR [65,66] suggest-
ing that several neurotransmitter systems could be
impaired in ADHD. Compared to WKY, SHR have lower
brain Ca2+ ATPase activity [67]. Because neurotransmitter
release is dependent on calcium influx, a disturbance inBehavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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the concentration gradient of calcium across the cell
membrane may decrease the influx of calcium ions into
the cell and impair neurotransmitter release [65].
Decreased calcium influx through NMDA channels would
also impair intra- and intercellular signalling as well as
LTP, the neuronal analogue of learning [4,68].
Calcyon, a transmembrane protein involved in DRD1/
DRD5 signalling, has been implicated in ADHD [69]. Pol-
ymorphisms of the calcyon gene (DRD1IP) have been
associated with both inattentive and hyperactive/impul-
sive subtypes of ADHD [Laurin et al., submitted]. Calcyon
enables the typically Gs-linked DRD1/DRD5 to switch
from Gs to Gq coupling, thereby stimulating inositol
1,4,5-triphosphate (IP3) turnover with resultant release of
calcium from intracellular stores. This effect requires a
priming step involving heterologous Gq-linked G-pro-
tein-coupled receptor activation. Subsequent DRD1 acti-
vation causes elevation of intracellular calcium that
triggers calcyon accumulation in the plasma membrane
[70]. SHR appear to have a disturbance in calcium metab-
olism. Increased intracellular calcium could interfere with
calcyon translocation to the cell membrane and thereby
impair DRD1/DRD5 function. Alternatively, altered cal-
cyon function could impair DRD1/DRD5 function by
affecting the switch from Gs to Gq coupling, thereby also
altering intracellular calcium concentration. These find-
ings suggest that the primary disturbance in ADHD may
be located in factors that regulate postsynaptic DRD1/
DRD5 signalling mechanisms, hence, calcyon and other
DRD1/DRD5 signalling-related proteins/peptides deserve
further investigation [Laurin et al, submitted]. The
hypothesis that calcyon may be a primary disturbance in
ADHD could be tested in animal models, particularly
SHR.
Dopamine
Dopamine neurons play an important modulatory role in
the brain [71]. Neurons that release dopamine influence
behaviour by exerting modulatory effects on the transfer
of information through neuronal circuits that connect
functionally distinct cortical areas to specific regions of
the striatum in parallel cortico-striato-thalamo-cortical
pathways. Dopamine assists in reprogramming the brain
by selectively reinforcing the weights of the synapses that
are active around the time of behavioural reinforcement
[4,72].
There are three major dopaminergic systems in the brain,
the mesolimbic, mesocortical and nigrostriatal pathways.
Mesolimbic dopamine neurons project from the ventral
tegmental area of the midbrain (VTA) to limbic areas of
the brain. The firing rate of dopamine neurons is
increased in response to unexpected reward and decreased
when a fully predicted reward is omitted [73,74]. It has
been suggested that deficient reinforcement of appropri-
ate behaviour and/or deficient extinction of previously
reinforced behaviour can give rise to ADHD symptoms of
delay aversion, hyperactivity in a familiar environment,
impulsiveness, deficient sustained attention, increased
behavioural variability and failure to extinguish previ-
ously acquired behaviour [4].
The mesocortical dopamine system originates in the VTA
and projects to cortical areas, including the prefrontal,
parietal and temporal cortex. These dopamine projections
modulate circuits that are known to play an important
role in a variety of executive functions, including motor
control, behavioural inhibition, attention, and working
memory [4,75]. Dopamine activation of DRD2 selectively
modulates neural activities associated with memory-
guided motor activity in delayed response tasks whereas
DRD1 are responsible for memory-related persistent acti-
vation of prefrontal cortex neurons [76]. Deficient
dopamine-mediated modulation of prefrontal cortical cir-
cuits has been suggested [4] to cause attention response
deficiencies (impaired orienting responses, saccadic eye
movements and responses towards a target) and impaired
executive functions (poor behavioural planning).
Nigrostriatal dopamine neurons project from the substan-
tia nigra pars compacta to the dorsal striatum (caudate
nucleus and putamen). Impaired dopamine modulation
of cortico-striato-thalamo-cortical circuits can impair
motor function and cause deficient habit learning i.e.
impaired nondeclarative memory formation [4]. These
impairments can give rise to apparent developmental
delay, clumsiness, and neurological "soft signs" [4].
Dopamine uptake, storage and/or metabolism are dis-
turbed in SHR [58,77], as has been proposed for children
and adults with ADHD [52,53]. Although the tissue con-
centration of dopamine, which reflects vesicle stores of
dopamine, is similar in SHR and WKY [78], dopamine
turnover which reflects release and metabolism of
dopamine was lower in adult SHR substantia nigra, VTA,
striatum and frontal cortex [78,79]. The dopamine metab-
olite, homovanillic acid, and the homovanillic acid /
dopamine ratio are much lower in several brain areas of
adult SHR compared to WKY. These findings are consist-
ent with increased expression of DAT1 increasing
dopamine re-uptake and reutilization thereby reducing
metabolism. The results could also be interpreted to sug-
gest that dopamine release is decreased and dopamine
transmission is impaired in SHR.
In vitro stimulation-evoked (electrical and/or exposure to
high K+ concentration) release of dopamine from termi-
nals of mesocortical, mesolimbic and nigrostriatal
dopamine neurons of SHR is significantly less than that ofBehavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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WKY [55,56,58,59,77,80]. A similar decrease in stimulus-
evoked release of dopamine was observed in SHR nucleus
accumbens shell in vivo [54]. The elevated dopamine con-
centration in the nucleus accumbens shell may have
increased activation of endogenous DRD2 autoreceptors
and thus reduced stimulus-evoked dopamine release [54].
In vitro DRD2-mediated inhibition of dopamine release
was greater in SHR caudate-putamen and nucleus
accumbens than WKY, while DRD2 function was
unchanged in prefrontal cortex of SHR [77]. Results are
consistent with increased endogenous activation of DRD2
in the nucleus accumbens while increased efficacy of
endogenous dopamine activation of DRD2 autoreceptors
was suggested to account for the decreased stimulus-
evoked release of dopamine in SHR striatum [77].
Increased DRD2 function was suggested to have occurred
in a compensatory reaction to abnormally elevated
dopamine levels at an early stage of development, perhaps
as a result of exposure to stress and/or a genetic defect
[80]. A likely explanation could also be that elevated
extracellular dopamine levels could have resulted from
decreased DAT1 expression during the first postnatal
month of SHR [50] which caused compensatory upregu-
lation of both DAT1 and DRD2 receptors [51,58,77].
Increased d-amphetamine stimulated, DAT-mediated,
release of dopamine from SHR prefrontal cortex and stria-
tum is consistent with upregulation of DAT1 in adult SHR
[58].
In agreement with decreased stimulus-evoked release of
dopamine, postsynaptic DRD1 are increased in the cau-
date-putamen and nucleus accumbens of SHR [51,81,82]
suggesting compensatory upregulation of postsynaptic
receptors.
Dopamine dysfunction may contribute to the altered rein-
forcement processes of ADHD [4,45]. DRD1 mediates
reinforcement by strengthening synaptic connections
between neurons (long-term potentiation, LTP) or weak-
ening synaptic connections (long-term depression, LTD)
in neural circuits that involve prefrontal cortex and/or
striatum (e.g. cortico-striato-thalamo-cortical circuits)
[74,83,84]. LTP is regarded as a neuronal correlate of
learning [68]. It requires interplay between several factors.
Among these is coincident glutamate stimulation of
NMDA receptors and local membrane depolarization suf-
ficient to remove the magnesium block of NMDA receptor
channels. Glutamate activation of AMPA receptors allows
influx of sodium ions and can thereby produce this depo-
larization. Activation of the DRD1-protein kinase A sig-
nalling pathway increases the mobilisation of AMPA and
NMDA receptors to the cell surface, thereby promoting
LTP [85-87].
Calcium enters the cell through the NMDA receptor chan-
nel, activates various protein kinases including calcium/
calmodulin-dependent protein kinase II, and mobilizes
"silent" AMPA receptors required for LTP to take place
[68]. NMDA receptor-induced excitation is enhanced by
DRD1 activation and attenuated by DRD2 activation [88-
90]. Thus DRD1 activation may synergistically increase
the excitatory actions of glutamate at NMDA receptors,
increasing the open time of NMDA channels and there-
fore increase the calcium signal. Activation of DRD1
receptors is required for stimulation of cAMP formation,
and subsequent activation of cAMP-dependent protein
kinase, phosphorylation of CREB and gene transcription
required for consolidation of memory traces [91].
NMDA receptors are required for LTP in the hippocampus
[68], in cortico-striatal synapses [92], and in the nucleus
accumbens [93]. Phasic application of dopamine in the
prefrontal cortex facilitates LTP, suggesting that dopamine
can promote reinforcement processes by strengthening
(or weakening) network connections in the prefrontal
cortex [94]. Bilateral infusion of a DRD1 agonist increased
attentional accuracy and facilitated short-term spatial
memory after delays of several seconds and impaired
memory of the location of a visual target after short
delays, thereby modulating short-term working memory
in a delay-dependent manner [95]. Effective decision
making requires the ability to adapt behaviour on the
basis of changes in emotional significance. Rats with
lesions of the orbitofrontal cortex showed increased pref-
erence for larger but delayed rewards whereas rats with
lesions of the basolateral amygdala showed increased
choice of small immediate rewards [96].
Within the striatum, LTP (and LTD) only occurs in the
presence of dopaminergic input [97]. Consistent with
decreased DRD1 activation in SHR giving rise to decreased
facilitation of NMDA receptor function and impaired
gene transcription, SHR have reduced expression of cal-
cium/calmodulin-dependent protein kinase II and c-fos
gene in the anterior striatum [98-100]. Decreased DRD1
function will alter transmission of signals in cortical and
striatal circuits of SHR and impair dopamine-mediated
cognitive function and reinforcement of appropriate
behaviour.
Deficient DRD1 function in SHR implies that only stimuli
with strong reinforcer value will release enough DA to
stimulate DRD1 sufficiently to facilitate NMDA receptor
function and produce phosphorylation of CREB and
other important proteins/peptides required for strength-
ening of synaptic connections in circuits representing
goal-directed learning and memory consolidation. Weak
stimuli will not cause behaviour to be reinforced in SHR
because of reduced activation of the DRD1 signallingBehavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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pathways. As suggested in the dynamic developmental
behavioural theory (DDT) of Sagvolden et al [4], SHR
have a steeper delay gradient, so decreased activation of
DRD1 signalling pathways in response to an unexpected
reinforcer would not strengthen synaptic connections in
circuits that were activated by stimuli some time prior to
the reinforcer with the result that more recently activated
behavioural circuits would be preferentially strengthened
and their memory consolidated.
The striatum is central to behavioural control and receives
the greatest density of dopamine input of all central nerv-
ous structures. Striatal dopamine hypofunction may be
associated with subtle motor control problems in children
with ADHD and SHR [4]. Impaired dopamine regulation
of striatal function may contribute to the poor motor
development associated with severe cases of ADHD [101].
Response "disinhibition" may be due to impaired motor
control associated with dopamine hypofunction in the
striatum rather than frontal lobe dysfunction [4]. Indeed,
motor control problems may explain a number of effects
including clumsiness, increased variability in speed, less
accurate response re-engagement, "failure to inhibit"
responses when quick reactions are required, impaired
orienting responses, increased number of responses with
extended reaction times, apparent developmental delay,
neurological "soft signs", and language delays [4].
Papa et al. [100] found decreased calcium/calmodulin-
dependent protein kinase II in the nucleus accumbens
shell but not the core of SHR when compared to WKY. The
mesolimbic dopamine projection to the shell subdivision
of the nucleus accumbens is responsible for motivation
and determines the amount of effort an animal is pre-
pared to exert in order to obtain a reward. Hypofunction
of the mesolimbic dopamine system will impair the func-
tion of the mesocortical and nigrostriatal dopamine sys-
tems by influencing dopamine release and the cortico-
striato-thalamo-cortical circuits that dopamine modu-
lates. This could impair learning and expression of goal-
directed behaviour thereby contributing to the aspects of
ADHD symptoms displayed by SHR [102].
Norepinephrine
In addition to the hypothesis that dopaminergic systems
are hypofunctional in ADHD, noradrenergic neurons
have been suggested to be poorly regulated and hyper-
functional in the prefrontal cortex of children with ADHD
[40,103,104]. Noradrenergic neurons appear to enhance
the signal-to-noise ratio in prefrontal and parietal cortices,
amplify responses to attended stimuli, and reduce
responses to irrelevant stimuli [71,105]. Both of these
functions are defective in ADHD [71].
The locus coeruleus diffusely innervates diverse regions
throughout the central nervous system including the
entire cerebral cortex, various subcortical areas, cerebel-
lum and spinal cord, and plays an important role in atten-
tion, arousal, orienting, and vigilance [40]. For example,
locus coeruleus neurons respond selectively to attended
(target) stimuli; tonic locus coeruleus activity corresponds
to arousal state, and both very low and very high locus
coeruleus activity are associated with impaired vigilance
[103,105]. Noradrenergic neurons that project from the
locus coeruleus to the prefrontal cortex release norepine-
phrine which helps to guide behaviour by modulating the
transfer of information through neuronal circuits that are
responsible for selective and sustained attention [40].
Norepinephrine, like dopamine, alters the strength of
neural connections leading to adaptive changes in behav-
iour. This occurs through activation of β -adrenoceptors
that stimulate cAMP formation, with subsequent activa-
tion of cAMP-dependent protein kinase, phosphorylation
of CREB and gene transcription required for consolida-
tion of memory traces in several brain areas, including
amygdala and hippocampus [91,106]. Dopamine and
norepinephrine act in concert to regulate prefrontal cortex
function and thereby ensure appropriate behaviour [103].
α 2-Adrenoceptors agonists enhance performance of tasks
requiring prefrontal cortex function while α 1-adrenocep-
tor agonists impair prefrontal cortex function [103]. Fur-
thermore,  α 1- and α 2-antagonists reverse these effects
[103,107]. Either excessive activation of α 1-adrenoceptors
or deficient α 2-adrenoceptor mediated modulation of pre-
frontal cortical circuits can impair prefrontal cortex func-
tion [103,108]. The prefrontal cortex projects to the VTA
and locus coeruleus, thereby influencing the firing rate of
both dopamine and norepinephrine neurons and impact-
ing on many cognitive processes [103].
The highly specific antagonist of NET1, atomoxetine, is as
effective as methylphenidate in treating ADHD [38,109],
further emphasizing an important role for the noradren-
ergic system in the disorder. However, atomoxetine also
increases synaptic availability of dopamine in the prefron-
tal cortex [110] which may contribute to its beneficial
effects. Drugs used to treat ADHD symptoms are likely to
have different effects on different neurotransmitter sys-
tems. Drugs that act on the noradrenergic system, such as
atomoxetine, tricyclic antidepressants like the NET1
blocker, desipramine, and α 2-adrenoceptor agonists such
as clonidine and guanfacine, have a different therapeutic
time-course compared to psychostimulants. Methylphe-
nidate produces amelioration of ADHD symptoms within
30 minutes and is short-acting whereas noradrenergic
drugs have to be administered for longer periods of time
before a therapeutic effect is observed, and improvement
is sustained for several months [38]. This suggests thatBehavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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noradrenergic drugs cause long-term adaptive changes
that are therapeutic. Chronic treatment with desipramine
produces a series of changes in presynaptic and postsyn-
aptic α - and β -adrenoceptors and causes long-term down-
regulation of cortical β -adrenoceptors [111-113]. This
suggests that behavioural improvement can perhaps be
achieved by decreased noradrenergic activation of cortical
β -adrenoceptors, thereby decreasing noradrenergic func-
tion, which is consistent with a hyperactive noradrenergic
system and the dopamine/norepinephrine imbalance
hypothesis of ADHD.
Disturbances in norepinephrine metabolism in SHR are
suggested by the finding that tyrosine hydroxylase gene
expression is higher in the ventrolateral medulla oblon-
gata of SHR than WKY [114], consistent with elevated
norepinephrine concentration in several brain areas of
SHR including locus coeruleus, substantia nigra and pre-
frontal cortex [79]. Increased norepinephrine concentra-
tions in SHR brain is consistent with downregulation of β -
adrenoceptors in cerebral cortex of SHR [115]. Further-
more, NET1 function is increased in SHR cerebral cortex
[115] which could increase uptake of dopamine into
noradrenergic terminals and varicosities and deplete
extracellular dopamine in the prefrontal cortex [116].
Evidence suggests that there is an imbalance between
dopaminergic and noradrenergic neurotransmission in
the prefrontal cortex of SHR [104]. While dopamine
release is decreased in SHR prefrontal cortex, norepine-
phrine concentrations are elevated. The noradrenergic sys-
tem appears to be hyperactive as a result of impaired α 2-
autoreceptor regulation [104].
Stimulus-evoked (electrically stimulated or K+-evoked)
release of norepinephrine from prefrontal cortex slices of
SHR was no different from that of WKY [117]. However,
α 2A-adrenoceptor mRNA levels were decreased in SHR
compared to WKY and α 2-autoreceptor-mediated inhibi-
tion of norepinephrine release was less efficient in SHR
than in WKY suggesting that α 2-adrenoceptor function is
impaired [117-119]. α 2A-Adrenoceptors are the subtype
specifically expressed in the prefrontal cortex, so impaired
α 2A-adrenoceptor function would be expected to impair
cognition [103,120].
Decreased α 2-autoreceptor-mediated regulation of nore-
pinephrine neurons and impaired inhibition of norepine-
phrine release may be particularly disruptive to the
function of target structures when the firing rate of locus
coeruleus neurons is high, causing excessive spillover of
norepinephrine. Repeatedly increased release of nore-
pinephrine from sympathetic nerve terminals could give
rise to the stress-dependent [60] development of hyper-
tension in SHR. Expression of the gene encoding Giα  the
G-protein subunit that inhibits cAMP formation from ATP
by adenylyl cyclase is increased in SHR aorta at 2 weeks of
age, possibly reflecting an attempt by a target organ to
decrease the effect of increased norepinephrine release
from sympathetic nerve endings. Poorly controlled nore-
pinephrine release could also give rise to excessive activa-
tion of α 1-adrenoceptors in the prefrontal cortex
impairing its function. Other noradrenergic terminal
areas in the central nervous system may be similarly
affected. These findings suggest that the noradrenergic sys-
tem is hyperactive in SHR, particularly in response to
stress, and supports the hypothesis that there is an imbal-
ance between norepinephrine hyperfunction and
dopamine hypofunction in ADHD.
Serotonin
Brain serotonin (5-hydroxytryptamine, 5-HT) function
has been suggested to be altered in SHR [121]. Higher
serum testosterone, and lower amygdala serotonin con-
tent has been associated with a mutation in the non-pseu-
doautosomal region unique to the Y-chromosome of SHR
[122]. Administration of a serotonin transporter inhibi-
tor, fenfluramine, evoked less prolactin secretion in SHR
than WKY [121]. Acute administration of the selective
serotonin reuptake inhibitor, citalopram, reduced hyper-
activity of SHR in an elevated plus-maze [123]. However,
there was no difference between SHR and WKY in mid-
brain, hippocampal, or striatal serotonin concentration or
serotonin uptake kinetics [123]. In addition, stressors
released serotonin in the locus coeruleus of SHR and WKY
rats to the same extent [124] and 5-HT2C receptor function
was reported to be unaltered in SHR compared to WKY
[125]. These findings do not support a role for serotonin
in the aetiology of ADHD symptoms in SHR.
Glutamate
In addition to decreased autoreceptor-mediated inhibi-
tion of norepinephrine release from SHR prefrontal cortex
slices, glutamate activation of AMPA receptors caused
greater release of norepinephrine from SHR prefrontal
cortex slices than WKY [126,127]. Glutamate is present in
micromolar concentrations in the extracellular space out-
side the synaptic cleft and regulates tonic dopamine con-
centration in the extracellular fluid [128-132]. Dopamine
release is increased by activation of AMPA receptors in rat
striatum [133,134]. Glutamate activation of NMDA recep-
tors upregulates DRD1 function by a direct protein-pro-
tein interaction at the carboxy terminals of both receptors
[135]. As suggested by Seeman and Madras [136], the
common defect in ADHD could be decreased extracellular
dopamine levels. This deficiency could result from
increased expression of DAT1, impaired dopamine syn-
thesis, impaired release, or impaired regulation of extra-
cellular dopamine by glutamate afferents from the
prefrontal cortex, hippocampus, or amygdala [102]. How-Behavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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ever, in vitro activation of AMPA receptors caused similar
fractional release of dopamine from SHR and WKY
nucleus accumbens core [134]. Unlike WKY, glutamate-
stimulated release of dopamine from the shell subdivi-
sion of SHR nucleus accumbens was significantly lower
than from the core subdivision of SHR, suggesting that the
shell may be particularly vulnerable to disturbances in
dopamine release [134].
Neural circuits that use glutamate as a neurotransmitter
are modulated by dopamine and norepinephrine. Future
studies should be aimed at investigating glutamate func-
tion in the brains of SHR. In particular, measuring gluta-
mate release in the prefrontal cortex and nucleus
accumbens using in vivo microdialysis during reinforce-
ment and extinction (hypothesized to be the major caus-
ative factors underlying ADHD [4]) may provide useful
information concerning afferent glutamate input to these
brain areas as a result of the additional demands of such
tasks.
Psychostimulants
Psychostimulants are the most effective drugs used in the
treatment of ADHD and provide a powerful means to gain
insight into the underlying disturbances of ADHD. d-
Amphetamine and methylphenidate reduced the ADHD-
like behaviour of SHR [137] [Sagvolden, unpublished;
Russell, unpublished]. The increase in DRD1 density
observed in SHR striatum is reversed by methylphenidate
treatment suggesting that psychostimulants reduce
ADHD-like behaviour of SHR by increasing dopamine
activation of DRD1 [51,81,82] thereby enabling
dopamine-mediated LTP and reinforcement mechanisms
to take place.
Psychostimulants changed the performance of SHR in
fixed-interval schedules of reinforcement of bar-presses by
lengthening the delay-of-reinforcement gradient. How-
ever, WKY performance changed to a greater extent than
SHR, suggesting that the effect of psychostimulant drugs
was less pronounced in SHR than in WKY [138]. The
reduced reactivity to psychostimulants may be associated
with abnormalities in DAT1 gene expression [50,51] [Mill
et al., unpublished] and dopamine hypofunction as a
result of adaptation to increased availability of dopamine
at an early stage of development with subsequent reorgan-
ization of neural mechanisms that control VTA dopamine
neuron function [139]. Further support for the hypothesis
that regulation of midbrain dopamine neurons is altered
in SHR was provided by the fact that repeated administra-
tion of methylphenidate (2.5 mg/kg) elicited locomotor
sensitization i.e. increased locomotor response to the
same dose of methylphenidate 3 days after cessation of
treatment in Sprague-Dawley and WKY rats but not in
SHR who were unaffected by the drug [140]. In vitro find-
ings provided further support, where methylphenidate
released significantly less dopamine from SHR nucleus
accumbens slices than WKY [58], and chronic methylphe-
nidate treatment (3 mg/kg for 2 weeks) increased endog-
enous dopamine activation of DRD2 in WKY striatum but
did not alter DRD2 function in SHR probably because
DRD2 were already up-regulated in SHR and no longer
responsive to increases in extracellular dopamine [141].
These results suggest that neural circuits have been altered
in SHR and that psychostimulant drugs affect SHR and
WKY brains differently. This finding stresses the impor-
tance of studying animal models of ADHD as it shows
that it cannot be assumed that drugs will have the same
effect in children with ADHD and controls.
Other animal models of ADHD
Several other animal models of ADHD have been pro-
posed. These models were developed through genetic
manipulation, exposure to toxins, rearing in social isola-
tion, or interference with neurochemical systems. How-
ever, several do not satisfy the criteria for animal models
of ADHD [45] and have therefore been excluded from the
present review. These include the Naples high-excitability
rat (NHE), WKHA rat, acallosal mouse, hyposexual rat,
PCB-exposed rat, lead-exposed mouse, and rat reared in
social isolation [45].
The reasons for exclusion are briefly as follows: NHE are
hyperreactive in a novel environment, they are not hyper-
active or impulsive in a familiar environment, and they
have not been shown to be impaired in sustained atten-
tion [142,143]. WKHA rats are hyperactive but they are
not impulsive [47,144-146]. The acallosal mouse
becomes hyperactive over time and shows impaired
acquisition of conditioned learning tasks [147]. However,
impulsiveness decreases over time with repeated testing
which is not characteristic of ADHD. Polychlorinated
biphenyls (PCBs) administered either pre- or postnatally
cause hyperactivity in rats but do not impair sustained
attention [148-150]. Postnatal exposure of infant mice to
lead causes ataxia and hyperactivity [151] but lead pro-
duces many other complications that would exclude a
diagnosis of ADHD. Rat pups reared in social isolation
display hyperactivity in a novel environment and
increased errors of omission and perseveration [152].
However, these rats are not impulsive and are unimpaired
in measures of task acquisition in the 5-choice serial reac-
tion time (5-CSRT) test of sustained attention. In addi-
tion, children reared in social isolation would not be
diagnosed as ADHD.
Coloboma mutant mouse
The SNAP-25 deficient mouse mutant coloboma (Cm/+)
is of interest to ADHD because SNAP-25 polymorphisms
have been associated with the disorder [153,154]. SNAP-Behavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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25 regulates membrane trafficking and is involved in the
release of all neurotransmitters as well as regulating trans-
location of proteins (e.g. NMDA receptor subunits) to the
cell membrane. Altered expression of SNAP-25 will there-
fore have diffuse effects on neuronal function. The SNAP-
25 deficient mouse mutant coloboma displays spontane-
ous hyperactivity [155] but lacks impulsiveness and has
not been shown to have problems with sustained atten-
tion. Although the SNAP-25 deficient mouse does not
model ADHD symptoms specifically, it may nevertheless
serve as a useful model of non-specific brain dysfunction
such as minimal brain disorder (MBD).
Depolarization-evoked (K+-evoked) release of glutamate
from cortical synaptosomes is reduced in the coloboma
mouse [156]. DRD2 expression is increased in the VTA
and substantia nigra, suggesting increased inhibition of
dopamine neuron firing rate [157]. Dopamine release and
dopamine metabolites (DOPAC and HVA) are decreased
in the striatum of coloboma mice which is consistent with
decreased dopamine release and turnover [156,158] i.e. a
hypofunctional dopaminergic system, similar to SHR.
Striatal DRD1 and DRD2 expression is unaltered in the
coloboma mouse [157]. Tyrosine hydroxylase expression
is unaltered in VTA and substantia nigra whereas tyrosine
hydroxylase and α 2A-adrenoceptor expression is increased
in the locus coeruleus of the coloboma mouse [157].
Noradrenergic function appears to be increased since
experimental depletion of norepinephrine by DSP-4
reduces the hyperactivity of coloboma mice [159]. This
suggests that motor activity in coloboma mice is caused by
a hyperactive noradrenergic system but the hyperactivity
is not completely abolished by depletion of norepine-
phrine, suggesting that additional factors contribute to the
mutant phenotype [159], perhaps the imbalance between
noradrenergic hyperfunction and dopamine hypofunc-
tion as suggested for SHR.
6-OHDA-Lesioned Rat
Neonatal 6-OHDA-lesioned rats are not impulsive but
they display hyperactivity and impaired learning in a spa-
tial discrimination task, which improves after methylphe-
nidate or d-amphetamine treatment [160-163]. Rat pups
lesioned on postnatal day 1 displayed hyperactivity in
adulthood [162]. They showed an initial decrease in spon-
taneous motor behaviour when placed in a novel environ-
ment, but after repeated testing their activity was
increased relative to controls [162]. Hyperactivity was
accompanied by decreased dopamine [162], increased
DRD4 [164], and increased serotonin transporter binding
in striatum but not cerebral cortex [165]. Hyperactivity
was not altered by DAT1 inhibitors but was greatly
reduced by DRD4 antagonists as well as inhibitors of
SERT1 and NET1 [160,161,164,166]. These findings sug-
gest that psychostimulants reduce hyperactivity of 6-
OHDA lesioned rats not by inhibiting DAT1 but by inhib-
iting norepinephrine and serotonin transporters. Inhibi-
tion of NET1 would reduce dopamine uptake into
noradrenergic terminals in several brain areas including
prefrontal cortex and nucleus accumbens.
DAT-Knockout Mouse
DAT-knockout (DAT-KO) mice lack the gene that encodes
DAT. These mice have been suggested as a model for
ADHD because they are hyperactive in novel situations
[167-169], have impaired extinction of responses in oper-
ant food reinforcement tasks [170]. They are also
impaired in learning and memory tasks [168,169]. Impul-
siveness has not been systematically investigated in DAT-
KO mice. Although the absence of DAT is an extreme
model of reduced midbrain DAT binding in adolescents
with ADHD [36] it also contrasts with several studies that
found increased DAT in striatum of ADHD children and
adults [10,15,35]. The DAT-KO mouse nevertheless pro-
vides useful information concerning the neurobiological
consequences of impaired DAT function.
Released dopamine is cleared at a slow rate giving rise to
a 5-fold elevation of extracellular tonic dopamine in the
striatum of DAT-KO mice i.e. a hyperdopaminergic state
[171]. Electrically stimulated release of dopamine is
decreased, suggesting that phasic release of dopamine is
reduced i.e. the dopamine system is hypofunctional [171]
similar to SHR and the coloboma mouse. However,
unlike SHR, striatal DRD2 autoreceptors controlling
dopamine synthesis are nonfunctional while DRD1 and
DRD2 are downregulated by approximately 50% in the
striatum of DAT-KO mice [171]. Hyperactivity in the
DAT1 knock-out mouse might be the result of increased
dopamine tone or decreased phasic dopamine release
with consequently impaired activation of postsynaptic
DRD1 required for LTP (and LTD) to produce changes in
synaptic strength necessary for associative learning and
reinforcement of appropriate behaviour.
Whereas specific inhibitors of NET1 or DAT1 did not
affect DAT-KO hyperactivity, inhibitors of the SERT1 as
well as drugs that activate the serotonergic system, such as
serotonin receptor agonists and serotonin precursors, dra-
matically reduced hyperactivity [168]. DAT-KO mice pro-
vide convincing evidence that hyperactivity induced by
high extracellular levels of dopamine can be reduced by
enhancing serotonergic tone i.e. psychostimulants do not
act via DAT1 to reduce hyperactivity in this model [168].
Interestingly, antagonists of the 5-HT2A receptor reverse
the behavioural deficits of DAT-KO mice [172] and poly-
morphisms of the 5-HT2A receptor gene have been associ-
ated with ADHD [173,174]. While this model provides
invaluable insight into possible mechanisms of psychos-
timulant action, the relevance of these findings to ADHDBehavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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is not clear since serotonin reuptake inhibitors are of lim-
ited value in treating ADHD as one of the side effects of
serotonin uptake inhibitors is stimulation of motor activ-
ity [38,168]. However, serotonin acts on a large number
of receptor subtypes each with different spatial location
and behavioural effects. Evidence obtained with the DAT-
KO mouse suggests that specific antagonists of the 5-HT2A
receptor deserve further investigation.
Interestingly, the DAT-knockdown (DAT-KD) mouse has
been suggested as a model for obsessive compulsive disor-
der and Tourette's syndrome [175]. DAT knockdown,
achieved by reducing DAT promotor strength, reduces
adult DAT expression to 10% of wild-type levels and raises
extracellular dopamine levels in the striatum to 170% of
wild-type controls [175]. Hyperdopaminergic DAT-KD
mice displayed excessive sequential stereotypy reflected as
a complex serial pattern of grooming actions becoming
more sequentially rigid and persistent. This type of behav-
iour is not characteristic of ADHD but may serve as a
model for Tourette's and obsessive compulsive disorder
[175]. Consistent with enhanced dopamine activation of
DRD1 receptors being responsible for the excessively rigid
serial pattern of instinctive grooming behaviour, DRD1
agonists produced similarly enhanced sequential stere-
otypy of syntactic grooming chains [175]. DAT-KD mice
also tend to be hyperactive, to walk in perseverative
straight paths, and to over-pursue certain incentive stim-
uli, consistent with obsessive compulsive disorder.
Poor 5-CSRT task performer
Rats that are selected for poor performance when trained
in the 5-CSRT task provide a useful model of ADHD in
that they are selected for deficient sustained attention,
they show poor choice accuracy towards the end of testing
sessions, and they demonstrate impulsiveness (premature
responding) [176,177]. Methylphenidate treatment
improved accuracy and reduced impulsiveness (at low
doses) in poor performers [177]. Poor 5-CSRT task per-
formers are not hyperactive and therefore may serve as a
model of the inattentive subtype of ADHD.
In normal animals, response accuracy is adversely affected
by activation of serotonin 5-HT1A receptors [178], while
activation of 5-HT2A receptors increases the number of
premature responses, suggesting that increased serotonin
tone could be responsible for impulsivity of poor per-
formers [179]. This is consistent with 5-HT2A receptor
antagonists reversing the behavioural deficits of DAT-KO
mice [172].
Evidence supports a role for dopamine in regulating the
level of performance in the 5-CSRT task. In normal ani-
mals, d-amphetamine-stimulated release of dopamine in
the nucleus accumbens caused a dose-dependent increase
in premature responding [178]. Microinfusion of a DRD1
agonist into the medial prefrontal cortex selectively
impaired the accuracy of attentional performance in high
performers in the 5-CSRT task [180]. In contrast, microin-
fusion of the DRD1 agonist into the medial prefrontal cor-
tex of poor performers enhanced the accuracy of
attentional performance; a low dose increased the speed
of making correct responses [180]. This finding once
again emphasizes the need to study animal models of
ADHD rather than normal animals in order to gain
insight into the mechanisms that underlie the beneficial
effects of drugs used to treat children with ADHD. Evi-
dence suggests that the nervous system is altered in the 5-
CSRT model of ADHD.
These results suggest that dopamine function is reduced in
poor performers of the 5-CRST task and that 5-HT2A antag-
onists may be beneficial in the treatment of ADHD.
Anoxia in Neonatal Rat
Anoxia increases the risk of ADHD [181]. Neonatal anoxia
caused a sequence of acute and persistent neurochemical
changes in rat monoaminergic systems as well as transient
hyperactivity and spatial memory impairment that per-
sisted into adulthood [182-184]. Acute anoxia caused a
transient decrease followed by an increase after 1 week in
cerebellar norepinephrine levels [183]. At the same time,
serotonin levels decreased while its metabolite, 5-hydrox-
yindoleacetic acid (5-HIAA), increased [183]. Striatal
dopamine and metabolite concentrations decreased and
then dopamine metabolites increased post ischaemia
[183]. The increase in serotonin and dopamine metabo-
lites persisted into adulthood, suggesting that dopamine
turnover is increased. Tyrosine hydroxylase mRNA levels
were increased in VTA and substantia nigra of perinatally
asphyxiated rats suggesting increased dopamine synthesis
consistent with increased turnover. However, DRD1 and
DRD2 mRNA levels were increased in the striatum sug-
gesting impaired release of dopamine [185]. These find-
ings demonstrate the complex temporal sequence of
compensatory changes that occur in monoaminergic sys-
tems following perinatal insult to the nervous system and
implicate all three monoaminergic systems in spatial
memory impairment.
Insight provided by animal models of ADHD
One of the most important findings is the fact that animal
models of both inattentive and hyperactive/impulsive
subtypes of ADHD respond differently to psychomotor
drugs when compared to controls suggesting that they
have altered neurotransmitter systems in the brain. This
emphasizes the need to study animal models of ADHD
rather than normal animals in order to gain insight into
the mechanisms that underlie the beneficial effects of
drugs used to treat children with ADHD.Behavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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Neuroadaptations leading to psychostimulant drug addic-
tion involve the same glutamate-dependent cellular
mechanisms that enable learning and memory [87]. Sim-
ilarly, neural mechanisms implicated in behavioural dis-
turbances of animal models of ADHD are consistent with
altered dopamine and/or norepinephrine mediated mod-
ulation of glutamate-dependent cellular mechanisms that
enable learning and memory.
The various animal models of ADHD focus on different
aspects of ADHD symptomatology and provide unique
insights into ADHD neurobiology. They also emphasize
the close interconnection between serotonergic,
noradrenergic and dopaminergic systems. Changes in any
one system can alter the function of the other monoamin-
ergic systems and alter the underlying neural circuits that
control behaviour.
There is convincing evidence of a dysfunctional dopamin-
ergic system in several models of ADHD. The dopaminer-
gic system appears to be hypofunctional in SHR, the
coloboma mutant mouse, 6-OHDA lesioned rat, DAT-KO
mouse (although extracellular hyperdopaminergia may
also contribute to its behaviour) and poor performers in
the 5-CSRT task. There is no convincing evidence to sug-
gest that the underlying disturbance is primarily located in
the serotonergic or other neurotransmitter system,
although amelioration of ADHD symptoms may be partly
mediated by drugs acting on the noradrenergic and sero-
tonergic systems.
The dynamic developmental theory of ADHD [4] explains
how behavioural changes associated with ADHD may
result from deficient reinforcement and extinction proc-
esses as a result of a hypofunctional dopaminergic system
and a steeper delay gradient in ADHD [4,186]. Impaired
function of the mesolimbic dopamine system can cause
ADHD symptoms of delay aversion, hyperactivity in a
familiar environment, impulsiveness, deficient sustained
attention, increased behavioural variability and failure to
extinguish previously acquired behaviour [4]. Deficient
mesocortical dopamine-mediated modulation of prefron-
tal cortical circuits can impair behavioural planning (exec-
utive function). Hypofunction of the nigrostriatal system
would impair dopamine modulation of cortico-striato-
thalamo-cortical circuits that control motor function giv-
ing rise to apparent developmental delay, clumsiness, and
neurological "soft signs" [4].
The development of ADHD symptoms could be the result
of inappropriately increased levels of dopamine at an
early stage of development causing compensatory changes
that subsequently give rise to hypofunctional dopamine
neurons and impaired reinforcement/extinction mecha-
nisms [4,139,186]. Children who have been exposed to
elevated levels of brain dopamine prenatally as a result of
mothers taking drugs of abuse, exhibit ADHD-like behav-
iour [187]. Exposure to drugs of abuse increases the extra-
cellular dopamine concentration which reduces
autoreceptor inhibition of VTA dopamine neurons and
increases glutamate-driven activity of dopamine-contain-
ing neurons [187-190]. The consequences of increased
extracellular dopamine is demonstrated in the DAT-KO
mouse which loses the normal inhibitory effect of DRD2
on dopamine neuron firing rate in the VTA and substantia
nigra, as well as dopamine release-regulating DRD2 func-
tion in the striatum [190]. The mechanism is suggested to
involve increased AMPA receptor-mediated excitatory
transmission and decreased inhibitory metabotropic
glutamate receptor function in VTA dopamine neurons
[187,188,191]. Increased activation by glutamate initially
causes sensitization of VTA dopamine neurons with sub-
sequent adaptations in the nucleus accumbens [191]. The
increased glutamate drive is suggested to lead to patho-
physiological consequences resulting from the high intra-
cellular concentrations of Ca2+  which gives rise to
impaired function of VTA dopamine neurons and adapta-
tion [191]. Similarly, ADHD symptoms may result from
adaptation to initially increased extracellular dopamine in
the VTA of the midbrain as a result of genetic and environ-
mental effects at a very early stage of development giving
rise to increased glutamate drive and subsequent loss of
function of dopamine neurons.
The dynamic developmental theory of ADHD [4] explains
how ADHD symptoms, including problems with sus-
tained attention, can result from impaired dopamine
function giving rise to a steeper delay gradient and poor
stimulus control of behaviour when reinforcers are infre-
quent. Sustained attention is also controlled by noradren-
ergic projections from the locus coeruleus to the
prefrontal cortex. There is considerable evidence to sug-
gest that the noradrenergic system is poorly controlled by
α 2-autoreceptors in SHR, particularly at high norepine-
phrine release rates. This may be seen as hyperactivity of
the noradrenergic system, especially when locus coeruleus
neurons are stimulated in states of increased arousal.
Increased release of norepinephrine from sympathetic
nerve endings can give rise to the development of hyper-
tension. Impaired regulation of norepinephrine release in
the prefrontal cortex could give rise to ADHD-like symp-
toms.
It is interesting to note that although the various animal
models have quite different origins, they have in common
either increased or decreased tonic dopamine and/or
decreased phasic release of dopamine. Some models also
display poor regulation of locus coeruleus neurons and
noradrenergic hyperactivity. These alterations may be pri-
mary or may reflect compensatory changes in response toBehavioral and Brain Functions 2005, 1:9 http://www.behavioralandbrainfunctions.com/content/1/1/9
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more basic disturbances in neurotransmission, such as
deficient SNAP-25 or impaired Ca2+ signalling.
Future research should focus on determining the precise
effects of psychostimulant drugs on the nervous system of
animal models of ADHD. Psychostimulants affect animal
models of ADHD and normal animals differently, sug-
gesting that the nervous system of the ADHD model has
undergone adaptive change which alters the effects of
drugs used to treat ADHD. DAT-KO mice provide con-
vincing evidence that psychostimulant drugs reduce
hyperactivity by enhancing serotonin tone. Antagonists of
the HT2Areceptor are reported to reverse ADHD-like
behaviour in some animal models. To test whether this is
a general finding of relevance to ADHD, other animal
models such as the SHR should be treated with
HT2Aantagonists to confirm whether their ADHD-like
behaviour is similarly reversed. Once this is established,
further testing to see if the beneficial effects of HT2A antag-
onists and psychostimulant drugs can be prevented by
blockers of postsynaptic DRD1 receptors would be of
interest, in order to test the dynamic developmental the-
ory of ADHD [4] proposal that ADHD-like symptoms can
be explained by deficient dopaminergic function and that
psychostimulants enhance phasic dopamine release.
ADHD is a heterogeneous disorder, suggested to result
from combinations of genetic and environmental factors.
Animal models can mimic only certain aspects of the
complex symptomatology of ADHD and at best provide
feasible hypotheses regarding the underlying causes of
specific aspects of ADHD behaviour. These hypotheses
can then be tested in the clinic. Animal models can also be
used to test potential drugs for the treatment of ADHD.
Future research on animal models of human disorders
will undoubtedly promote a better understanding of the
contribution of specific neurobiological factors to behav-
ioural components like attention, reinforcement and
extinction that seem to be important for understanding
ADHD.
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